About Us
Our mission is to improve human drug safety assessment through advanced primate in vitro models that support the FDA Modernization Act 2.0 and 3.0 and the 3R principles—replacing, reducing, and refining animal use.
Our Story
Exir Bio was founded in 2022 in Silicon Valley to improve translational relevance of drug safety evaluation using New Approach Methods (NAMs). The company brings together a multidisciplinary team with expertise in stem cell biology, in vitro systems, AI and computational genomics, along with leadership in finance and management.
Exir Bio’s platform generates nonhuman primate (NHP)-derived tissues in vitro, enabling direct in vitro–to–in vivo translation within the same species. This approach improves the predictivity of safety assessment, reduces reliance on live animal studies, and helps shorten the path to clinical development.
We are committed to advancing translational science while fostering a collaborative environment for innovation and training.
